Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Method for predicting platinum chemosensitivity of ovarian cancer patient by combining serum glycosylation modification with CA125

A CA125, glycosylation technology, applied in the biological field, can solve problems such as markers that have not yet been found, and achieve the effect of improving the survival rate

Pending Publication Date: 2020-03-27
THE OBSTETRICS & GYNECOLOGY HOSPITAL OF FUDAN UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Some researchers have tried to find markers to distinguish the sensitivity of ovarian cancer patients to chemotherapy, so as to evaluate the treatment plan of patients before treatment, but so far, no suitable markers have been found, and the use of glycosylation modification in pre-treatment No studies have been reported to differentiate chemotherapy sensitivity in patients with ovarian cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for predicting platinum chemosensitivity of ovarian cancer patient by combining serum glycosylation modification with CA125
  • Method for predicting platinum chemosensitivity of ovarian cancer patient by combining serum glycosylation modification with CA125

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] 1) Collect serum samples from ovarian cancer patients before treatment. One year after the end of the platinum-based chemotherapy regimen, 16 patients relapsed within half a year after the completion of platinum-based chemotherapy, and they were chemotherapy-resistant patients; 48 patients relapsed after half a year, and they were chemotherapy-sensitive patients.

[0024] 2) According to the test procedure described in the content of the invention above, detect the glycosylation modification of the patient's serum, calculate the relative expression of á2,3 sialic acid type N-glycan chains, combine the serum CA125 content of the patient, and use SPSS software to perform binary logistic Regression analysis to obtain predicted probabilities.

[0025] 3) With 0.24 as the critical value, if the predicted probability is greater than 0.24, it is classified as a chemoresistant group, and if it is less than 0.24, it is classified as a chemosensitive group.

[0026] 4) When 0.24...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

Glycosylation modification in serum of an ovarian cancer patient before treatment is detected, and the sensitivity of the ovarian cancer patient to platinum chemotherapeutic drugs is subjected to prognosis evaluation by combining alpha 2, 3 sialic acid N-sugar chains with CA125. A detection object of the kit is serum of an ovarian cancer patient before treatment; the method comprises the followingsteps: detecting serum glycosylation modification by using an analytical instrument, calculating the relative expression quantity of alpha 2, 3 sialic acid type N-sugar chains, and performing binarylogistic regression analysis in combination with the content of CA125 in serum of a patient by using SPSS software to obtain a prediction probability; taking 0.24 as a critical value, if the prediction probability is greater than 0.24, determining that the patient is a drug-resistant patient, and if the prediction probability is less than 0.24, determining that the patient is a sensitive patient.The method has the advantages that the chemotherapy effect of the medicine on the patient is predicted by utilizing the proper marker, a treatment scheme more suitable for the patient is selected, andthe survival rate of the ovarian cancer patient is further improved.

Description

technical field [0001] The present invention relates to the field of biotechnology. Background technique [0002] Ovarian cancer is the most lethal gynecological tumor. At present, serum CA125 and ultrasound are the most common detection methods; most patients are treated with tumor annihilation combined with chemotherapy. Currently, the first-line chemotherapeutic drug for ovarian cancer is platinum combined with paclitaxel. Although most patients are sensitive to platinum-based drugs during the initial chemotherapy, most patients will relapse with drug resistance, so the five-year survival rate of ovarian cancer patients is not high, and the prognosis is poor. Clinically, 6 months is usually used as the time point to distinguish patients' sensitivity to drugs. If the time from the end of platinum-based chemotherapy to relapse is less than 6 months, it is defined as a drug-resistant patient; if it is longer than 6 months, it is defined as a sensitive patient. If appropr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02G01N30/06G01N30/08
CPCG01N30/02G01N30/06G01N30/08G01N2030/067
Inventor 徐丛剑赵然任士芳顾建新王宜生张晓燕
Owner THE OBSTETRICS & GYNECOLOGY HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com